Last updated: July 27, 2026
GENENTECH, INC. v. SHANGHAI HENLIUS BIOTECH, INC. (2:25-cv-14648): Litigation Summary, Claims, Key Dates, and Patent Exposure
Executive summary: The docket 2:25-cv-14648 is filed by Genentech, Inc. against Shanghai Henlius Biotech, Inc. A litigation summary that is accurate at the claims-and-patents level requires access to the complaint, asserted patent list, case schedule, and any motion outcomes. Those docket-specific details are not present in the input provided here, so a complete and accurate analysis cannot be produced without risking fabrication.
What patents are asserted in GENENTECH, INC. v. SHANGHAI HENLIUS BIOTECH, INC. (2:25-cv-14648)?
Answer: Not provided in the available information.
Which Genentech product(s) and active ingredient(s) does the case target?
Answer: Not provided in the available information.
Is the case about biosimilar, interchangeability, or manufacturing/induced infringement?
Answer: Not provided in the available information.
Which claim types are pleaded (infringement, induced, contributory, declaratory judgment)?
Answer: Not provided in the available information.
What is the procedural posture in 2:25-cv-14648 and what happens next?
Answer: Not provided in the available information.
When was the case filed and what court issued it?
Answer: Not provided in the available information.
Has Genentech moved for preliminary relief or a preliminary injunction?
Answer: Not provided in the available information.
Have there been responsive pleadings, claim construction, or scheduled hearings?
Answer: Not provided in the available information.
What is Genentech’s litigation theory against Shanghai Henlius in 2:25-cv-14648?
Answer: Not provided in the available information.
Does the complaint rely on a specific FDA submission or patent “notice” theory?
Answer: Not provided in the available information.
What product characteristics are central to infringement allegations?
Answer: Not provided in the available information.
How does this case affect biosimilar launch risk for Henlius and its pipeline?
Answer: Not provided in the available information.
What launch timing constraints would typically flow from an injunction request?
Answer: Not provided in the available information.
Does the case appear to target a single SKU or multiple dosage forms/strengths?
Answer: Not provided in the available information.
Are there settlement indications in the record (stipulations, dismissal without prejudice, consent judgments)?
Answer: Not provided in the available information.
What prior and parallel litigation exists between Genentech and Henlius on the same/related patents?
Answer: Not provided in the available information.
Are there related cases in the same district or consolidated proceedings?
Answer: Not provided in the available information.
Have any earlier dockets established claim-construction or invalidity positions?
Answer: Not provided in the available information.
How strong is Genentech’s patent estate for the asserted patents in 2:25-cv-14648?
Answer: Not provided in the available information.
What are the earliest effective filing dates, expiration dates, and any PTA adjustments (if applicable)?
Answer: Not provided in the available information.
Are any asserted patents subject to the same invalidity theories (e.g., anticipation, obviousness, lack of written description/enablement)?
Answer: Not provided in the available information.
What is the history of enforcement for the asserted patents (wins/losses)?
Answer: Not provided in the available information.
What defenses are raised by Shanghai Henlius in 2:25-cv-14648 (non-infringement, invalidity, procedural defenses)?
Answer: Not provided in the available information.
Do defenses include design-around positions or alternative claim scope interpretations?
Answer: Not provided in the available information.
Are there jurisdiction or standing challenges alleged in the pleadings?
Answer: Not provided in the available information.
What is the likely discovery and claim construction timeline for 2:25-cv-14648?
Answer: Not provided in the available information.
What are common milestones that would apply once scheduling is set?
Answer: Not provided in the available information.
What settlement terms usually appear in Genentech biosimilar patent litigations, and does the docket show similar patterns?
Answer: Not provided in the available information.
Are there indications of a covenant-not-to-sue, licensing agreement, or dismissal with prejudice pending payment?
Answer: Not provided in the available information.
What generic or biosimilar entry risks exist during the litigation window for the relevant product category?
Answer: Not provided in the available information.
Does the case hinge on FDA approval status, litigation stay, or carve-outs?
Answer: Not provided in the available information.
Is the risk specific to a particular pathway (BLA biosimilar, 351(k), extrapolation, or interchangeability)?
Answer: Not provided in the available information.
Orange Book and FDA listing status: What does the docket imply for exclusivity and approvals?
Answer: Not provided in the available information.
Are the patents Orange Book-listed or part of the BLA/Biosimilar patent listing regime?
Answer: Not provided in the available information.
Has FDA approval been granted or stayed, based on the FDA notice/PNR framework?
Answer: Not provided in the available information.
Key Takeaways
No litigation-level conclusions can be stated from the docket identifier alone without the asserted patent list and procedural record.
FAQs
- What does docket “2:25-cv-14648” tell analysts about the asserted patent basis?
- Does this case involve a biosimilar pathway or an Orange Book small-molecule dispute?
- What claim-construction issues typically drive outcomes in Genentech versus biosimilar litigations?
- How can injunction risk be inferred from early docket events?
- What settlement structures most frequently resolve these disputes?
References
No sources are cited because no docket record, complaint, or court filings were provided in the input.
